Get the Stockscreener App
132.68
0.01%
-0.010
After Hours:
132.61
-0.07
-0.05%
Apogee Therapeutics Inc stock is traded at $132.68, with a volume of 5.03M.
It is down -0.01% in the last 24 hours and up +63.48% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$132.69
Open:
$132.78
24h Volume:
5.03M
Relative Volume:
2.30
Market Cap:
$9.98B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
-30.66
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
+46.80%
1M Performance:
+63.48%
6M Performance:
+69.91%
1Y Performance:
+208.63%
1-Day Range:
$132.60
$132.89
1-Week Range:
$132.45
$133.16
52-Week Range:
$34.34
$133.16
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
132.68 | 9.98B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
480.18 | 120.61B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
620.14 | 65.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.65 | 53.02B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.17 | 39.26B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
178.17 | 36.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
AbbVie to buy Apogee Therapeutics for $10.9 billion in cash - MSN
Apogee Therapeutics Insider Sold Shares Worth $3,500,640, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Carl Dambkowski Sells 26,400 Shares of Apogee Ther - GuruFocus
Apogee Therapeutics CEO Henderson sells $10.6m in common stock - Investing.com
Apogee Therapeutics CMO Carl Dambkowski sells $3.5m in stock - Investing.com
Apogee Therapeutics CMO Carl Dambkowski sells $3.5m in stock By Investing.com - Investing.com South Africa
Form 4 Apogee Therapeutics Inc For: 24 June By Investing.com - Investing.com South Africa
Apogee Therapeutics(APGE.US) Officer Sells US$3.5 Million in Common Stock - Moomoo
Apogee Therapeutics(APGE.US) Officer Sells US$10.6 Million in Common Stock - Moomoo
Apogee Therapeutics (APGE) CEO executes 80,000-share planned stock sale - Stock Titan
Apogee Therapeutics (APGE) CMO sells 26,400 shares in planned open-market trade - Stock Titan
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc.APGE - Business Wire
APGE Downgraded by Stifel -- Price Target Raised to $135 - GuruFocus
Apogee Therapeutics : APGE - 24/7 Wall St.
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition By Investing.com - Investing.com South Africa
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition - Investing.com UK
BIG POTENTIAL UPSWING : APGE STOCK ANALYSIS | APOGEE THERAPEUTICS INC STOCK Alavés Vs Barcelona (ZJ4SE9HqGu) - Mshale
AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion To Rebuild Its Pipeline - Sahm
Mid-Cap Stocks Surge: Apogee Therapeutics (APGE) and Virtu Finan - GuruFocus
Form 13D/A Apogee Therapeutics For: 23 June By Investing.com - Investing.com South Africa
Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
APGE Downgraded by Citigroup -- Price Target Raised to $135 - GuruFocus
Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share - Stock Titan
APGE Downgraded by Wedbush -- Rating Adjusted to Neutral - GuruFocus
Apogee Therapeutics Cut to Hold From Buy by Deutsche Bank - Moomoo
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - Benzinga
APGE Maintained by RBC Capital -- Price Target Raised to $135 - GuruFocus
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Gaining IL-13 Antibody Zumilokibart - BioPharm International
AbbVie (ABBV) Pursues Acquisition of Apogee Therapeutics - GuruFocus
American biopharmaceutical company AbbVie acquires Apogee Therapeutics for $10.9 billion - AKM.RU
Daily short sale tracking: Apogee Therapeutics's short volume increased by 7 million, with a short sale ratio of 14% - Moomoo
UBS downgrades Apogee Therapeutics stock rating on AbbVie deal By Investing.com - Investing.com India
Guggenheim Downgrades Apogee Therapeutics to Neutral From Buy - marketscreener.com
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - Yahoo Finance
Deutsche Bank Downgrades Apogee Therapeutics to Hold From Buy, Adjusts Price Target to $135 From $116 - marketscreener.com
RBC Removes 'Speculative Risk' From Apogee Therapeutics, Raises Price Target to $135 From $97 Amid AbbVie Deal, Keeps Sector Perform Rating - marketscreener.com
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders - Sahm
AbbVie Inc. (ABBV) Apogee Therapeutics, Inc.M&A CallSlideshow (NYSE:ABBV) 2026-06-23 - Seeking Alpha
UBS downgrades Apogee Therapeutics stock rating on AbbVie deal - Investing.com UK
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday - Sahm
AbbVie (ABBV) Set to Acquire Apogee Therapeutics (APGE) for $11 Billion - GuruFocus
REGRTW Biotech Opp.AbbVie to acquire Apogee Therapeutics - TradingView
ABBV Acquires Apogee Therapeutics for $10.9 Billion to Boost Imm - GuruFocus
5 Stocks Paying Off Big Time - Insider Monkey
Form 144 APOGEE THERAPEUTICS INC For: 22 June By Investing.com - Investing.com India
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio - Investing News Network
Apogee Therapeutics | DEFA14A: Others - Moomoo
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger - Insider Monkey
Apogee Therapeutics (APGE) Sees Significant Stock Surge - GuruFocus
Form 144 APOGEE THERAPEUTICS INC For: 22 June - Investing.com UK
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):